R. Scott Greer is Director at NEKTAR THERAPEUTICS (NKTR). They have made 9 open-market trades across 4 companies since 2014, most recently 2026-09-23.
CIK 0001211703
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
5 open-market purchases totalling $799K since 2014, against 4 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| NKTR | SELL | 2020-07-09 | 2020-07-10 | $25.00 | $375K | -0.5% | -11.5% | -24.9% |
| NKTR | SELL | 2018-09-04 | 2018-09-06 | $67.39 | $674K | -11.0% | -21.1% | -42.0% |
| NKTR | SELL | 2018-06-04 | 2018-06-06 | $60.28 | $603K | -4.6% | -22.2% | +11.9% |
| SIEN | BUY | 2018-05-07 | 2018-05-09 | $13.50 | $300K | +0.8% | +13.6% | +24.8% |
| NKTR | SELL | 2018-04-06 | 2018-04-09 | $92.22 | $2.8M | -14.6% | -26.3% | -55.0% |
| NKTR | BUY | 2016-10-24 | 2016-10-25 | $13.50 | $203K | -5.4% | +3.7% | -6.6% |
| VSAR | BUY | 2015-11-11 | 2015-11-13 | $10.17 | $102K | -23.1% | -0.6% | -33.9% |
| VSAR | BUY | 2015-01-27 | 2015-01-27 | $17.25 | $95K | -23.1% | -0.6% | -0.6% |
| ASPX | BUY | 2014-07-16 | 2014-07-16 | $19.25 | $100K | N/A | N/A | N/A |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.